|
|
||||||||
Max Planck Institut für Physiologische und Klinische Forschung, W. G. Kerckhoff Institut, 61231 Bad Nauheim, Germany
| |
ABSTRACT |
|---|
|
|
|---|
In
addition to the well-documented ability of calcitonin to lower blood
calcium levels, blood-borne calcitonin may also affect neurons located
outside the blood-brain barrier, e.g., in the subfornical organ (SFO),
where numerous receptors for this peptide have been described. In an in
vitro preparation of the rat SFO, calcitonin activated 61% of 36 neurons, only 1 neuron was inhibited, and the remainder were
unresponsive. All but two of the neurons excited by
10
7 M calcitonin were also
stimulated by 10
7 M ANG II.
The threshold concentration for the excitatory effects of calcitonin
was 10
9 M and was thus
similar to ANG II. Like ANG II, subcutaneous injection of calcitonin
stimulated water intake, although to a lower extent. These results
suggest that blood-borne calcitonin could stimulate drinking by its
excitatory effect on neurons in the SFO. Calcitonin, which is released
during food intake, might be involved in prandial drinking, which is
presently considered an acquired behavior.
drinking; thirst; osmoregulation; electrophysiology; thyroid; angiotensin II
| |
INTRODUCTION |
|---|
|
|
|---|
CALCITONIN IS A 32-AMINO ACID peptide hormone that is produced by parafollicular cells of the thyroid gland and released into the general circulation in response to a rise in the plasma level of calcium (2, 3) and also in response to (or even in anticipation of) food intake (20, 26, 27) as a condition in which plasma calcium levels may increase. Calcitonin is predominantly known for its role in body calcium homeostasis, and, together with parathyroid hormone and calciferol, it ensures the tight control of plasma calcium levels. In the periphery it reduces osteoclastic activity, increases the calcium excretion via the kidneys, and slows the motility of the gastrointestinal tract postprandially (3). Calcitonin has not been shown to be involved in body fluid homeostasis, although a connection between calcitonin and the renin-angiotensin system is suggested by data showing that peripheral calcitonin can cause an increase in plasma renin activity; however, this increase was not associated with an increased blood pressure (5).
Central intracerebroventricular applications of calcitonin have been shown to cause analgesia (4), decreased food intake (17), and a decrease in gastric acid secretion and gastrointestinal motility (2, 3). These and other central effects of calcitonin are thought to be due to different types of calcitonin receptors (10) primarily located inside the blood-brain barrier (BBB) that are most likely stimulated by a brain-intrinsic form of calcitonin (22), because peripheral calcitonin does not cross the BBB in significant amounts (6).
In the rat subfornical organ (SFO) and other circumventricular organs, central nervous structures located on the blood side of the BBB, a high density of calcitonin receptors was demonstrated by in vivo or in vitro receptor autoradiography (10, 21, 30), suggesting that blood-borne calcitonin might indeed act on neurons in the central nervous system. However, nothing is known so far about the possible physiological functions of these receptors, which are accessible to blood-borne calcitonin.
One of the best-investigated functions of the SFO is the increase in water intake in response to elevated plasma levels of ANG II (13). It has been amply documented that blood-borne ANG II can reach and activate neurons in the SFO via the open BBB by acting on ANG II receptors of the AT1 type that are abundant in the SFO and thus stimulate drinking (7, 11, 13).
The aim of this study was to obtain a first characterization of the effects of calcitonin on the activity of neurons in a circumventricular organ using an in vitro slice preparation of the SFO. The well-described SFO-mediated dipsogenic action of ANG II allowed a first assessment of the possible physiological function of blood-borne calcitonin acting on brain structures by comparison of the actions of peripherally applied calcitonin and ANG II on water intake.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Male adult Wistar rats (180-200 g) were decapitated, and their
brains were quickly removed and superfused with ice-cold artificial cerebrospinal fluid (aCSF) of the following composition (in mM): 124 NaCl, 5 KCl, 1.2 NaH2PO4,
1.3 MgSO4, 1.2 CaCl2, 26 NaHCO3, and 10 glucose,
equilibrated with 95% O2-5%
CO2, pH 7.4, at 290 mosmol/kg. The
brain was trimmed to a square block containing the entire
hypothalamus, from which a coronal section was cut at the level
of the anterior commissure. A slice of the body of the fornix
containing the entire SFO was cut by hand and preincubated in aCSF at
35°C for 2 h before recording. The SFO slice was transferred to the
recording chamber and fixed to the bottom of the chamber with a small
metal weight. The gold-plated recording chamber was made from solid
brass and, when perfused with aCSF, contained a fluid volume of ~0.7
ml. The chamber was constantly perfused with aCSF at a rate of 1.6 ml/min. The aCSF entering the recording chamber was prewarmed to the
same temperature as the solution already present in the chamber. The
temperature was kept constant at 37.0°C by means of a Peltier
element. Extracellular recordings were made from SFO neurons using
glass-coated platinum-iridium electrodes. The SFO could easily be
identified by its protrusion into the third ventricle and the lateral
blood vessels lining the organ on both sides. ANG II and rat calcitonin
(both from Sigma, Deisenhofen, Germany) were added to the aCSF shortly
before application. Both drugs were stored in frozen aliquots
(
24°C) and, during an experiment, were kept on ice until
use. After a stable recording from a single neuron had been
established, its responsiveness was tested by switching to a perfusion
solution containing the drug under consideration. The recorded action
potentials were amplified and displayed on a storage oscilloscope
(Gould) and were, after passing a window discriminator (World Precision Instruments, New Haven, CT), analyzed with custom-made software (Spike2
from Cambridge Electronic Design, Cambridge, UK) on a personal
computer.
In general, 10 ml of aCSF containing calcitonin or ANG II were
superfused per stimulus. The concentration of ANG II
(10
7 M) was chosen
according to previous experiments that showed that this concentration
induced clearly visible responses with minimum desensitization. In the
experiments investigating possible interferences of calcitonin with the
central renin-angiotensin system, the converting enzyme inhibitor
captopril
(10
5-10
4
M, Sigma) or the ANG II receptor antagonist losartan
(10
6-10
5
M; a gift from Merck Sharp & Dohme, West Point, PA) was coapplied with
an effective dose of calcitonin. From the continuously recorded ratemeter counts, the average discharge rate of each neuron was evaluated for 60 s before the stimulus. This value (referred to as
"control") was subtracted from all subsequent changes in firing rate, and the results were expressed in "%change of control." If
the averaged change of discharge rate during the entire response time
was larger than ±20%, the neuron was considered sensitive to the
applied substance. Furthermore, the effects of both agents had to be
reversible to be included in this study to avoid possible false
positive responses. To induce synaptic blockade, the slice was perfused
with the low-Ca2+ (0.3 mM), high-Mg2+ (9.0 mM)
aCSF for at least 10 min before the agonist superfusion began, and
superfusion was maintained for at least 5 min after the agonist
infusion had been stopped.
Water intake was investigated in male Wistar rats (180-200 g)
using an automated system (Omnitech, Columbus, OH) that monitored locomotor activity and food and water intake one time every minute and
stored data directly on a computer using Integra software (Omnitech).
Animals were adapted to the cages (40 × 40 cm) for at least 12 h
before the experiment started, and their food and water intake as well
as their locomotor activity was continuously recorded. Rats were fed on
ground rat chow. Grinding of the chow was necessary for precise
registration of food intake, because it prevented the removing of
pellets from the food container that rested on an electric balance.
Water bottles were fixed upside down on a holder that was mounted on an
electric balance (sensitivity 0.1 g) and were connected via tubing to a
drinking spout. Access to food was blocked 1 h before the experiment
started to avoid interference with prandial drinking. All drugs were
dissolved in sterile saline and were injected subcutaneously (200 µl
per rat) with small syringes (Omnican, 29 gauge, 0.5 ml; Braun,
Melsungen, Germany) at the end of the activity phase (9-10 AM).
ANG II was injected in a known effective concentration (0.2 mg/kg,
i.e., 2 × 10
4 M per
rat), and a similar concentration was used for calcitonin (1.4 mg/kg,
i.e., 4 × 10
4 M per
rat). In the experiments investigating possible interferences of
calcitonin with the renin-angiotensin system, 200 µl losartan (30 mg/kg, i.e., 6.5 × 10
2 M per rat) was
subcutaneously injected 30 min before the injection of calcitonin or
saline.
Various plasma parameters were determined from the blood of eight male
rats. The animals were decapitated 60 min after the injection of
calcitonin (200 µl, 4 × 10
4 M), and the plasma was
separated by rapid centrifugation for 10 min, with 4,000 U/min, at
4°C (Sigma centrifuge) in heparinized (heparin, 20 µl/ml blood;
Promonta, Hamburg, Germany) tubes. Total plasma calcium
was determined with a flame photometer (Eppendorf FCM 6341), and plasma
osmolality was measured with an osmometer (Westcor 5500, Logan, UT).
Mean values in the text are given with the standard error of the mean.
Statistical significance was evaluated using Mann-Whitney rank sum test
(Sigma Stat), and differences were regarded as significant with
P < 0.05.
| |
RESULTS |
|---|
|
|
|---|
Electrophysiological study.
In this study, only those neurons were included that could be tested
for their responsiveness to ANG II as well as calcitonin, both peptides
being superfused in the same concentrations and usually for the same
time (6 min). Superfusion of calcitonin at 10
7 M caused an excitation
in 61% (n = 36) of all neurons
tested, only 1 neuron (3%) was inhibited, and the remainder were
unresponsive. Cells recorded from the central medial portion of the SFO
were activated by calcitonin with a similar frequency (12 out of 17 neurons tested) as were cells recorded from the central lateral portions (8 out of 15 neurons tested). Figure
1 shows a continuous ratemeter recording of
a spontaneously active rat SFO neuron in which superfusion of
calcitonin caused an excitatory effect that was dose dependent with a
threshold concentration
<10
8 M. The
inset of Fig. 1 displays the averaged
dose response relationship of five neurons (tested with the identical
protocol as the original recording in Fig. 1) examined in a range
between 10
11 and
10
7 M, indicating
10
9-10
8
M as the average threshold concentration for the calcitonin-induced excitation. The similarity of the effects of calcitonin and ANG II is
shown in the example in Fig. 2, which is a
continuous ratemeter recording of an SFO neuron in which superfusion
with identical concentrations of ANG II and calcitonin caused
excitatory responses of similar magnitude, although in this case with a
slightly shorter response to ANG II compared with calcitonin, which is
due to a slightly smaller (7 ml instead of the usual 10 ml) application volume of the drug. Representative segments of the original spike recordings are shown in the top trace
of Fig. 2, in the presence and absence of both peptides. The average
signal-to-noise ratio under our recording conditions was 13:1
(n = 36). Comparing the excitatory
responses of those neurons on which ANG II and calcitonin had been
applied for the same time and in the same concentration (10
7 M), we found that the
mean ANG II-induced excitation was 2.8 ± 0.3 impulses/s and thus
not different from the calcitonin-induced excitation of 2.8 ± 0.3 impulses/s (n = 16). Similarly, no
difference could be observed in the peak (bin width 30 s) response (4.6 ± 0.5 impulses/s for ANG II vs. 4.1 ± 0.4 impulses/s for
calcitonin) and the onset of the excitatory effect (64 ± 10 s after
ANG II vs. 70 ± 8 s after calcitonin). None of these
effects were statistically different from each other except that the
duration of the calcitonin response (759 ± 45 s) was significantly
longer (P < 0.01, paired t-test) than the response of ANG II
(542 ± 37 s). As shown in Table 1, all but two of the
neurons that were excited by calcitonin could also be excited by
superfusion with ANG II at the same concentration (10
7 M). Superfusion of ANG
II (10
7 M) caused an
excitation of 83% of all cells tested
(n = 36), and the remainder were
unresponsive.
|
|
|
6 M) alone had either no
effect (see example in Fig. 3) or caused a
small inhibitory effect (
26 ± 2%) on the spontaneous
activity of 6 out of 13 SFO neurons, possibly indicating
angiotensinergic, excitatory interactions among neurons in the rat SFO.
However, this dose of losartan did not affect (inhibit) the
calcitonin-induced excitation (Fig. 3), although in this concentration
it completely abolished the ANG II-induced excitation in each of four
neurons tested. Superfusion with captopril
(10
5 M), which effectively
blocked ANG I-induced excitation at this concentration (not shown), had
no effect on the calcitonin-induced excitation. Superfusion with
captopril alone at this concentration resulted in a small inhibitory
effect (
6 ± 2%) in three out of nine neurons, and the
remaining cells were not affected.
|
|
Drinking experiments.
Subcutaneous injection of calcitonin (4 × 10
4 M, 200 µl) caused 12 out of 19 rats to drink water within the 2-h time period after the
injection (Fig.
5A).
Similarly, injection of ANG II (2 × 10
4 M, 200 µl) caused 16 out of 20 rats to drink water (Fig.
5B). Only 6 out of 33 rats that
received a subcutaneous injection of 200 µl of saline consumed water
within the observation period (not shown). The average amount of water
consumed by all rats, including those that did not drink at all, was
0.8 ± 0.2 ml 2 h after calcitonin and 2.8 ± 0.4 ml 2 h after
ANG II, and thus was significantly different from the control rats,
which drank 0.09 ± 0.05 ml (Fig. 6).
The onset of the drinking response was more rapid after the injection
of ANG II compared with calcitonin, resulting in a highly significant
water intake already after 30 min. The water intake in response to
calcitonin was significant only after 60 min compared with the
controls, which received the same amount of isotonic saline at the same
time. Injection of calcitonin together with ANG II in the indicated
concentrations resulted in an increase in water intake after 120 min
(3.5 ± 0.8 ml; n = 8) that was not
significantly higher than the water intake seen after ANG II alone
(Fig. 6).
|
|
2 M) that is known to
abolish ANG II-induced drinking in rats (Fig. 6). Pretreating rats with
the same amount of losartan 30 min before the subcutaneous injection of
calcitonin did not prevent the dipsogenic action of calcitonin; the
observed water intake of 1.0 ± 0.4 ml after 2 h was significantly
different from the control value.
Calcitonin effects on plasma calcium and osmotic concentration.
The total calcium concentration in the blood plasma of eight rats
treated with calcitonin (200 µl, 4 × 10
4 M) was 2.3 ± 0.1 mM
60 min after the injection and, thus, was significantly lower
(P < 0.001) in comparison with the
control level of 2.9 ± 0.1 mM determined in eight rats that had
received the same volume of vehicle. In the same two groups of animals, those treated with calcitonin revealed a significantly reduced plasma
osmolality of 285 ± 1 mosmol/kg in comparison to 289 ± 1 mosmol/kg determined in the controls
(P < 0.05). The injection of
losartan (200 µl, 6.5 × 10
2 M) caused no change in
plasma calcium levels (3.0 ± 0.1 mM,
n = 4) and did not antagonize the
reduction in plasma calcium (2.3 ± 0.1 mM;
n = 4) caused by calcitonin injections
(200 µl, 4 × 10
4 M)
when administered 30 min before (P < 0.05).
| |
DISCUSSION |
|---|
|
|
|---|
This study shows that calcitonin has a strong excitatory effect on the majority of neurons in the SFO of rats. The excitatory effect of calcitonin was dose dependent and reversible and was primarily observed on SFO neurons that could in addition be activated by ANG II. The similarity of the effects of ANG II and calcitonin on largely identical neurons in the rat SFO led to the prediction that peripheral calcitonin, like ANG II, should also increase water intake. This hypothesis could be confirmed experimentally by showing that subcutaneously applied calcitonin caused a significantly increased water intake in water-sated rats. These results suggest that blood-borne calcitonin may directly affect central neurons and that the physiological functions should be similar to the functions of ANG II on SFO-mediated effects.
The SFO-mediated water intake in response to ANG II and the excitatory effect on SFO neurons have been shown to be mediated by the AT1-receptor subtype (7, 11). The persistence of the excitatory action of calcitonin on SFO neurons in vitro, when ANG II effects had been abolished by an effective dose of the AT1 antagonist losartan or by the converting-enzyme inhibitor captopril, indicates that the neuronal effect of calcitonin was not mediated in one way or another by ANG II. Peripheral application of calcitonin and of the related peptide amylin has been shown to enhance plasma renin activity in rats and humans without affecting the blood pressure (5). However, for the present study, the presumption that calcitonin effects, secondary to the stimulation of renin release and subsequently enhanced formation of ANG II, might account alone for its dipsogenic action is also excluded by the persistence of the calcitonin-induced drinking after AT1 receptor blockade with losartan.
Plasma levels of calcitonin in rats (and humans) under control
conditions are 40-100 pg/ml (i.e., 1-3 × 10
11 M) (3, 18-20) and
are thus similar to the plasma levels of ANG II in the same species
(1-10 × 10
11 M)
(12, 15). The plasma levels of calcitonin are positively correlated
with the Ca2+ concentration in the
plasma, differ with age and sex of the animals, and increase in
response to several physiological factors such as pregnancy and
lactation (3) and notably with (and even in anticipation of) food
intake, which has been shown to increase plasma levels of calcitonin to
600-1,000 pg/ml (i.e., 2-3 × 10
10 M) (20, 27).
On the basis of the similarities in plasma concentration of both peptides and their similar effect on neuronal activity in vitro, it can be speculated that both peptides should cause similar SFO-mediated effects in vivo. The data of the drinking studies indicate at least the possibility that blood-borne calcitonin might act on the SFO to stimulate water intake, although it might also, or even primarily, be involved in other SFO-mediated functions, like salt or calcium appetite or release of arginine vasopressin.
The smaller and, compared with ANG II, delayed drinking response might partly be explained by a slightly higher sensitivity of rat SFO neurons to equimolar doses of ANG II under identical conditions (Rauch and Schmid, unpublished observations) and by a possible direct renal effect of calcitonin, leading to an increased excretion of calcium, sodium, potassium, and chloride ions (1, 3) (unpublished observations), which in summary cause a significant decrease in plasma osmolality, which might diminish the SFO-mediated dipsogenic effect of calcitonin by inhibiting osmosensory structures.
A reduction in food intake is a well-established response to centrally as well as peripherally applied calcitonin (8, 29). The reduction in water intake observed after central applications of calcitonin intracerebroventricularly or into the lateral hypothalamus (25, 29) is presumably a consequence of the reduced food intake (17). Electrophysiological studies investigating the effect of calcitonin on the electrical activity of thalamic and hypothalamic neurons revealed primarily inhibitory effects on neuronal activity (4, 9, 25, 28). The strong inhibitory effect on the electrical activity of neurons in these studies is in sharp contrast to the almost exclusively excitatory effect of calcitonin on SFO neurons in our experiments and adds to the specificity of the observed effect. In other words, centrally (icv or intrahypothalamic), unlike peripherally, applied calcitonin should not cause the same stimulatory effect on water intake as centrally applied ANG II, which is known to stimulate many hypothalamic neurons located inside the BBB and possibly mediating dipsogenic responses (11, 13). Furthermore, it has been shown that peripherally applied calcitonin does not cross the BBB in significant amounts (6) and that the physiologically relevant ligand for calcitonin receptors located inside the BBB might be different from the calcitonin that is released from the thyroid and that circulates in the blood (14, 22). All these pieces of evidence taken together suggest that the newly described SFO-mediated effects of calcitonin should clearly be separated from the so-far-known "central" effects of calcitonin (3).
Receptors for calcitonin have been described in various regions of the rat brain (16), with particularly high concentrations in circumventricular organs (30) including the SFO, which showed strong labeling after intravenous application of radioiodinated calcitonin (21). The calcitonin receptors in the SFO showed no cross-reactivity with ANG II (21), ACTH, and parathyroid hormone (30), thus underlining the specificity of these receptors. Recent autoradiographic and molecular cloning studies characterized three different receptor subtypes (C1a, C1b, and C3) of calcitonin or calcitonin-like receptors in the rat brain, each subtype with a slightly different distribution pattern in the rat brain (10, 23, 24). Despite the fact that so far no receptor-specific agonists or antagonists are available for each of these (and possibly other and as yet unidentified) receptor subtypes, all three of these and other related receptor subtypes are expressed in the SFO in high quantities (10, 24). However, it is of minor importance for the physiological relevance of the action of calcitonin in the SFO which receptor subtype is primarily responsible for the almost exclusively excitatory neuronal response. Physiologically it is also of minor importance for the described SFO-mediated effects whether the brain-intrinsic ligand for calcitonin receptors is actually calcitonin or a structurally related peptide (22), because the calcitonin receptors located in the SFO are definitely accessible to blood-borne calcitonin which originates mainly from the thyroid gland.
Perspectives
In summary, it can be concluded that physiological conditions that cause a significant rise in plasma levels of calcitonin, e.g., food intake and elevated levels of calciferol, during pregnancy and lactation, when there is a strong calcium demand (3), should result in an activation of neurons in the SFO, and thus it may cause thirst and possibly other SFO-mediated responses like salt appetite or release of vasopressin. It is tempting to speculate that prandial drinking, which is so far regarded to be a learned behavior, might actually be caused by circulating peptides. Blood-borne calcitonin might act on structures outside the BBB to cause a reduction in food intake or an altered appetite for calcium-containing food. These important questions have to be addressed in future physiological experiments, and the specific brain site of action for circulating calcitonin has to be characterized by direct microapplication and ablation studies.| |
ACKNOWLEDGEMENTS |
|---|
The authors thank Professor E. Simon for constant support and for critical reading of the manuscript. The expert technical assistance of G. Jurat is greatly appreciated.
| |
FOOTNOTES |
|---|
This work was supported by grant Si 230/8-2 from Deutsche Forschungsgemeinschaft.
Address for reprint requests: H. A. Schmid, Max Planck Institut für Physiol. und Klin. Forschung, W. G. Kerckhoff Institut, Parkstrasse 1, 61231 Bad Nauheim, Germany.
Received 10 November 1997; accepted in final form 23 February 1998.
| |
REFERENCES |
|---|
|
|
|---|
1.
Agus, Z. S.,
A. Wasserstein,
and
S. Goldfarb.
PTH, calcitonin, cyclic nucleotides and the kidney.
Annu. Rev. Physiol.
43:
583-595,
1981[Medline].
2.
Austin, L. A.,
and
H. Heath.
Calcitonin: physiology and pathophysiology.
N. Engl. J. Med.
304:
269-278,
1981[Medline].
3.
Azria, M.
The Calcitonins. Basel, Switzerland: Karger, 1989.
4.
Braga, P. C.,
M. Dal Sasso,
A. Bernini,
A. Pollo,
and
E. Carbone.
Antinociceptive activity of salmon calcitonin: electrophysiological correlates in a rat chronic pain model.
Neurosci. Lett.
151:
85-88,
1993[Medline].
5.
Clementi, G.,
E. Rapisarda,
C. E. Fiore,
A. Prato,
M. Amico-Roxas,
C. Millia,
R. Bernardini,
S. Maugeri,
and
U. Scapagnini.
Effects of salmon calcitonin on plasma renin activity and systolic blood pressure in the rat.
Neurosci. Lett.
66:
351-355,
1986[Medline].
6.
Flynn, J. J.,
D. L. Margules,
and
C. W. Cooper.
Presence of immunoreactive calcitonin in the hypothalamus and pituitary lobes of rats.
Brain Res. Bull.
6:
547-549,
1981[Medline].
7.
Fregly, M. J.,
and
N. E. Rowland.
Effect of nonpeptide angiotensin II receptor antagonist DUP 753 on angiotensin-related water intake in rats.
Brain Res. Bull.
27:
97-100,
1991[Medline].
8.
Gaggi, R.,
E. Beltrandi,
R. Dall'Olio,
and
S. Ferri.
Relationships between hypocalcaemic and anorectic effect of calcitonin in the rat.
Pharmacol. Res. Commun.
17:
209-215,
1985[Medline].
9.
Gerber, U.,
D. Felix,
M. Felder,
and
W. Schaffner.
The effects of calcitonin on central neurons in the rat.
Neurosci. Lett.
60:
343-348,
1985[Medline].
10.
Hilton, J. M.,
S. Y. Chai,
and
P. M. Sexton.
In vitro autoradiographic localization of the calcitonin receptor isoforms, C1a and C1b, in rat brain.
Neuroscience
69:
1223-1237,
1995[Medline].
11.
Li, Z.,
and
A. V. Ferguson.
Angiotensin-II responsiveness of rat paraventricular and subfornical organ neurons in-vitro.
Neuroscience
55:
197-207,
1993[Medline].
12.
Mann, J. F.,
A. K. Johnson,
and
D. Ganten.
Plasma angiotensin II: dipsogenic levels and angiotensin-generating capacity of renin.
Am. J. Physiol.
238 (Regulatory Integrative Comp. Physiol. 7):
R372-R377,
1980
13.
McKinley, M. J.,
R. M. McAllen,
F. A. O. Mendelsohn,
A. M. Allen,
S. Y. Chai,
and
B. J. Oldfield.
Circumventricular organs: neuroendocrine interfaces between the brain and the hemal milieu.
Front. Neuroendocrinol.
11:
91-127,
1990.
14.
Muff, R.,
W. Born,
and
J. A. Fischer.
Receptors for calcitonin, calcitonin gene related peptide, amylin, and adrenomedullin.
Can. J. Physiol. Pharmacol.
73:
963-967,
1995[Medline].
15.
Nussberger, J.,
and
H. R. Brunner.
Measurement of angiotensins in plasma.
In: The Renin-Angiotensin System, edited by J. I. S. Robertson,
and M. G. Nicholls. London, UK: Mosby, 1993, p. 15.1-15.13.
16.
Olgiati, V. R.,
F. Guidobono,
C. Netti,
and
A. Pecile.
Localization of calcitonin binding sites in rat central nervous system: evidence of its neuroactivity.
Brain Res.
265:
209-215,
1983[Medline].
17.
Plata-Salaman, C. R.,
and
Y. Oomura.
Calcitonin as a feeding suppresant: localization of central action to the cerebral III ventricle.
Physiol. Behav.
40:
501-513,
1987[Medline].
18.
Roos, B. A.,
C. W. Cooper,
A. L. Frelinger,
and
L. J. Deftos.
Acute and chronic fluctuations of immunoreactive and biologically active plasma calcitonin in the rat.
Endocrinology
103:
2180-2186,
1978[Abstract].
19.
Roos, B. A.,
L. J. Deftos,
G. Roberts,
P. Wilson,
and
L. Bundy.
Radioimmunoassay of calcitonin in plasma, normal thyroid, and medullary thyroid carcinoma of the rat.
J. Lab. Clin. Med.
88:
173-182,
1976[Medline].
20.
Roos, B. A.,
M. Yoon,
S. V. Cutshaw,
and
D. N. Kalu.
Calcium regulatory action of endogenous rat calcitonin demonstrated by passive immunization with calcitonin antibodies.
Endocrinology
107:
1320-1326,
1980[Abstract].
21.
Rouleau, M. F.,
H. Warshawsky,
and
D. Goltzman.
Specific receptors for calcitonin in the subfornical organ of the brain.
Brain
107:
107-114,
1984
22.
Sexton, P. M.,
and
J. M. Hilton.
Biologically active salmon calcitonin-like peptide is present in rat brain.
Brain Res.
596:
279-284,
1992[Medline].
23.
Sexton, P. M.,
J. S. McKenzie,
and
F. A. O. Mendelsohn.
Evidence for a new subclass of calcitonin/calcitonin gene-related peptide binding site in rat brain.
Neurochem. Int.
12:
323-335,
1988.
24.
Sexton, P. M.,
G. Paxinos,
M. A. Kenney,
P. J. Wookey,
and
K. Beaumont.
In vitro autoradiographic localization of amylin binding sites in rat brain.
Neuroscience
62:
553-567,
1994[Medline].
25.
Shimizu, N.,
and
Y. Oomura.
Calcitonin-induced anorexia in rats: evidence for its inhibitory action on lateral hypothalamic chemosensitive neurons.
Brain Res.
367:
128-140,
1986[Medline].
26.
Talmage, R. V.,
S. H. Doppelt,
and
C. W. Cooper.
Relationship of blood concentrations of calcium, phosphate, gastrin and calcitonin to the onset of feeding in the rat.
Proc. Soc. Exp. Biol. Med.
149:
855-859,
1975[Abstract].
27.
Talmage, R. V.,
P. H. Hirsch,
and
J. VanderWiel.
Calcitonin, feeding and calcium conservation.
In: Calcitonin, edited by A. Pecile. Milan, Italy: Int. Cong. Ser., 1981, p. 96-109.
28.
Twery, M. J.,
and
R. L. Moss.
Calcitonin and calcitonin gene-related peptide alter the excitability of neurons in rat forebrain.
Peptides
6:
373-378,
1985[Medline].
29.
Twery, M. J.,
J. F. Obie,
and
C. W. Cooper.
Ability of calcitonins to alter food and water consumption in the rat.
Peptides
3:
749-755,
1982[Medline].
30.
Van Houten, M.,
A. J. Rizzo,
D. Goltzman,
and
B. I. Posner.
Brain receptors for blood-borne calcitonin in rats: circumventricular localization and vasopressin-resistant deficiency in hereditary diabetes insipidus.
Endocrinology
111:
1704-1710,
1982[Abstract].
This article has been cited by other articles:
![]() |
T. Riediger, H. A. Schmid, T. Lutz, and E. Simon Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2001; 281(6): R1833 - R1843. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Tordoff Calcium: Taste, Intake, and Appetite Physiol Rev, October 1, 2001; 81(4): 1567 - 1597. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Simon Interface Properties of Circumventricular Organs in Salt and Fluid Balance Physiology, April 1, 2000; 15(2): 61 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hosono, H. A. Schmid, K. Kanosue, and E. Simon Neuronal actions of oxytocin on the subfornical organ of male rats Am J Physiol Endocrinol Metab, June 1, 1999; 276(6): E1004 - E1008. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rauch and H. A. Schmid Functional evidence for subfornical organ-intrinsic conversion of angiotensin I to angiotensin II Am J Physiol Regulatory Integrative Comp Physiol, June 1, 1999; 276(6): R1630 - R1638. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Riediger, M. Rauch, and H. A. Schmid Actions of amylin on subfornical organ neurons and on drinking behavior in rats Am J Physiol Regulatory Integrative Comp Physiol, February 1, 1999; 276(2): R514 - R521. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Scrogin, A. K. Johnson, and H. A. Schmid Multiple receptor subtypes mediate the effects of serotonin on rat subfornical organ neurons Am J Physiol Regulatory Integrative Comp Physiol, December 1, 1998; 275(6): R2035 - R2042. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |